About US
Contact us
-
Is Sanofi destined to be 'small player' in MS?Sanofi ($SNY) CEO Chris Viehbacher(photo) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme. But advances by other companies are making it diffi2012/2/6
-
FDA talks, but doctors don't necessarily listenPoor FDA. It takes flak every time a drug spawns unexpected side effects. But when it tries to warn doctors about those side effects--and offers advice for preventing them--few physicians are listen2012/2/3
-
Gloom for the pharma industry, yes. Doom? NoAstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spat2012/2/3
-
As blockbuster drugs fade, so does TV advertisingThe DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 20072012/2/3
-
FDA's new-drug approvals of 20112011 was a big year for drugmakers seeking to get their innovative products approved, as the FDA blessed 30 new drugs, a 7-year high. Among the lucky ones were Johnson & Johnson ($JNJ) and GlaxoSm2012/2/2
-
Roche results spotlight targeted-drug strategyAfter a series of Big Pharma letdowns, Roche's ($RHHBY) results announcement was a series of positives: An increase in 2011 net income, a sales-growth forecast in the "low to mid-single digits," and2012/2/2
-
Pfizer pulls mixed-up contraceptive pillsPill mix-ups and potency questions have prompted dozens of recalls in recent months. This time, the potential for both has Pfizer ($PFE)pulling 1 million packages of contraceptive pills. The balance2012/2/2
-
WSJ: Another executive shake-up at J&J's McNeil unitJohnson & Johnson ($JNJ) is taking an eraser to its McNeil Consumer Healthcare org chart again. Less than 12 months after a management shake-up put them in positions crucial to a McNeil turnarou2012/2/1
-
Pfizer, Lilly earnings drop on new generic rivalsPfizer ($PFE) and Eli Lilly ($LLY) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earning2012/2/1
-
Spain's drug spending drops as pharma debt mountsSpain is trying to fix its prescription-drugs spending, but so far, it's only managed to cause drugmakers pain. As PharmaTimes reports, the austerity-minded country cut its drug spending8.8% last ye2012/2/1